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Abstract
Background: With widespread use of antiretroviral (ARV) drugs in Africa, one of the major potential challenges is
the risk of emergence of ARV drug-resistant HIV strains. Our objective is to evaluate the virological failure and
genotypic drug-resistance mutations in patients receiving first-line highly active antiretroviral therapy (HAART) in
routine clinics that use the World Health Organization public health approach to monitor antiretroviral treatment
(ART) in Togo.
Methods: Patients on HAART for one year (10-14 months) were enrolled between April and October 2008 at three
sites in Lomé, the capital city of Togo. Plasma viral load was measured with the NucliSENS EasyQ HIV-1 assay
(Biomérieux, Lyon, France) and/or a Generic viral load assay (Biocentric, Bandol, France). Genotypic drug-resistance
testing was performed with an inhouse assay on plasma samples from patients with viral loads of more than 1000
copies/ml. CD4 cell counts and demographic data were also obtained from medical records.
Results: A total of 188 patients receiving first-line antiretroviral treatment were enrolled, and 58 (30.8%) of them
experienced virologic failure. Drug-resistance mutations were present in 46 patients, corresponding to 24.5% of all
patients enrolled in the study. All 46 patients were resistant to non-nucleoside reverse-transcriptase inhibitors
(NNRTIs): of these, 12 were resistant only to NNRTIs, 25 to NNRTIs and lamivudine/emtricitabine, and eight to all
three drugs of their ARV regimes. Importantly, eight patients were already predicted to be resistant to etravirine,
the new NNRTI, and three patients harboured the K65R mutation, inducing major resistance to tenofovir.
Conclusions: In Togo, efforts to provide access to ARV therapy for infected persons have increased since 2003, and
scaling up of ART started in 2007. The high number of resistant strains observed in Togo shows clearly that the
emergence of HIV drug resistance is of increasing concern in countries where ART is now widely used, and can
compromise the long-term success of first- and second-line ART.
Background
Implementation of antiretroviral therapy (ART) is recog-
nized as a public health priority in resource-limited
countries. In order to allow a rapid roll out of ART,
countries use the World Health Organization (WHO)
public health approach, which proposes standard first-
line therapy, together with treatment initiation and
switch guided by clinical disease progression and, where
possible, with monitoring of CD4 cell counts [1]. The
standard therapy consists of two nucleoside reverse
transcriptase inhibitors (NRTIs) (3TC+AZT/d4T) and
one non-nucleoside reverse transcriptase inhibitor
(NRRTI) (EFV/NVP).
In 2010, these guidelines were revised and recom-
mended less toxic drugs in first-line therapy by repla-
cing stavudine (d4T) with tenofovir (TDF) [2]. Although
a more strategic monitoring for ART efficacy is now
also recommended, virological monitoring is still not
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Saharan Africa due to the absence of adequate labora-
tory facilities and insufficient financial means. In addi-
tion, deficiencies in health systems and resources, such
as unreliable supply systems, storage and the lack of
qualified personnel to prescribe and monitor patients on
ART, could also create conditions for accelerated devel-
opment of HIV resistance to antiretroviral (ARV) drugs.
It is thus important to evaluate the outcome and effec-
tiveness of ART programmes in routine care settings in
resource-limited countries to evaluate whether the
empirical second-line treatment recommended by WHO
would still be effective.
Togo is a small country of 5.5 million inhabitants,
located in west Africa, with an estimated HIV preva-
lence of around 3% in the general population [3]. Scal-
ing up of ART started in 2007, and approximately 7000
HIV-1-infected individuals were receiving ART by the
end of 2007. Treatment became free of charge by the
e n do f2 0 0 8a n d ,t o d a y ,m o r et h a n1 7 , 0 0 0p e o p l ea r e
receiving ART, which corresponds to coverage of 33%.
Here we describe virological outcome and emergence of
drug resistance in a cross-sectional study among HIV-1-
infected patients treated according to the national guide-
lines in hospitals in Lomé, the capital city of Togo.
Methods
A total of 188 HIV-1-positive patients receiving first-line
ART for 12 months (+/-2 months) were consecutively
enrolled between April and October 2008 in three sites
in Lomé: the University Hospital Tokoin; and two non-
governmental organizations for HIV care, (EVT (Espoir
Vie Togo) and CRIPS (Centre de Réflexion et d’Initiative
pour la Promotion de la Santé). The study was approved
by the National Ethics Comitee and Ministry of Health
(N°0269/2007/MS/DGS/DPLET/CBRS). Only patients
who declared that they were ARV treatment naïve prior
to the start of first-line treatment and those without
prior use of ARVs for prevention of mother to child
transmission of HIV were included in this study. After
written informed consent, whole blood was collected
and plasma was separated from cells by centrifugation
at 3000rpm for five minutes and stored at -80°C in
three aliquots.
Whole blood less than six hours old was used to
determine the CD4 lymphocyte counts using a FACS-
CALIBUR flow cytometer (Becton Dickinson, San Jose,
CA). Plasma viral load was measured with the Nucli-
SENS EasyQ HIV-1 assay (Biomérieux, Lyon, France)
and/or a Generic viral load assay (Biocentric, Bandol,
France) [4]; the detection limits of the tests are 50 and
300 copies/ml, respectively. Genotypic drug-resistance
testing was performed on samples with HIV-1 RNA
levels equal to or above 1000 copies/ml using a
previously described in-house assay [5]. Amino acid
sequences were analyzed for the presence of mutations
in protease and RT genes with the drug-resistance inter-
pretation algorithm from ANRS (version July 2010)
(http://www.hivfrenchresistance.org/). HIV-1 subtypes/
CRFs were determined by phylogenetic tree and recom-
bination analysis as previously decribed [6].
Results
During the study period, 580 HIV-1-infected patients
attended one of the three clincs for their follow-up visit
at M12, and a total of 188 were included in this study.
The median duration of ARV therapy prior to study
enrollment was 12 months, ranging from 10 to 14
months. The median age of patients was 37 years (IQR
32-43), and only 66 (35.1%) were male (Table 1).
National guidelines for patient monitoring recommend
monthly clinical visits and CD4 counts at start and
every six months. CD4 counts were available for 160
patients at treatment initiation; a median CD4 cell
count of 100 cells/mm
3 (IQR 54-173) was seen, which
increased to a median of 293 cells/mm
3 (IQR 188-431)
among the same 160 patients at the time of enrolment
in this study, i.e., about 12 months later.
However, CD4 count increases were lower for the
patients with virological failure, i.e., from 98 cells/mm
3
(IQR 97-154) to 121 cells/mm
3 (IQR 50-249) versus 112
Table 1 Patient characteristics and HIV-1 variants
Characteristic Patients (n = 188) Number
(%)
Age, median years 37 (IQR 32-43)
Male sex 66 (35.1)
Treatment interruption (days)
[1-30] 82 (43.6)
>30 22 (11.7)
Total 104 (55.3)
CD4 lymphocyte at enrolment (n =
160)
CD4 count, median cells/mm
3 100 (IQR 54-173)
CD4 lymphocyte at end point (n =
160)
CD4 count, median cells/mm
3 293 (IQR 188-431)
Viral load at end point ≥1000 copies/
ml
58 (30.9)
Genotypic drug-resistance mutations 46 (24.5)
HIV subtypes/CRFs
CRF02 26
CRF06 6
G1
Unique recombinant forms
a 13
a.The following unique recombinant forms were observed: CRF02/A3 (n = 2),
CRF02/CRF06 (n = 1), CRF02/U (n = 2), G/A (n = 1), G/A3 (n = 1), G/A/CRF02 (n
= 1), G/CRF06 (n = 1), G/CRF02 (n = 2), CRF02/CRF06/U (n = 1), J/K/U (n = 1);
U = Unknown subtype/CRF
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3 (IQR 54-176) to 347 cells/mm
3 (IQR 269-
475). With the exception of two patients, all received
the generic drug, Triomune, a fixed-dose combination
of stavudine (d4T), lamivudine (3TC) and nevirapine
(NVP). The other two patients received AZT+3TC+EFV
or AZT+3TC+IDV. Importantly, during the 12-month
ART period, 104 (52.7%) patients had interrupted their
treatment; the duration of this interruption ranged from
o n et o1 6 8d a y s ,a n df o r2 2p a t i e n t s ,t h i sp e r i o d
exceeded one month. Treatment interruption was
reported for patients with and without virological failure
at comparable rates.
For 58 (30.8%) patients, plasma viral load (VL) was
above 1000 copies/ml, and for nine of them, VL was
between 1000 and 5000 copies/ml. Genotypic drug-
resistance testing analyses were done on 56 samples for
which sufficient material was available. Mutations con-
ferring resistance to NRTIs were detected in 46 of 56
(82.2%) patients with VLs above 1000 copies/ml, includ-
ing seven of the nine patients with VLs between 1000
and 5000 copies/ml. This corresponds to at least 24.5%
of patients receiving ART for 12 months.
Details of the drug-resistance profiles and correspond-
ing patient characteristics are shown in Table 2. All
patients were resistant to NNRTIs: 12 were resistant
only to NNRTIs, with the remainder resistant to
NNRTIs and other drugs. Among the NNRTI-associated
resistance mutations, 29 (60 . 4 % )o c c u r r e da tp o s i t i o n
Y181, 17 (35.4%) at K103 and 10 (20.8%) at G190 (Table
2). V106A/M, K101E and Y188C/L were noted in four,
three and two patients, respectively. Importantly, eight
patients were already predicted to be resistant to etravir-
ine, the new NNRTI, either because they harboured the
single Y181V mutation (n = 3) or due to the presence
of both Y181C and H221Y mutations (n = 5). Among
the 46 ARV-resistant patients, 25 also harboured the
M184V mutation conferring resistance to 3TC/FTC;
among them, eight patients were also resistant to the
other NRTI drug in their regimen because of the high
number of TAMs (n = 4), or the presence of the
Q151M (n = 1) or the K65R (n = 3) mutation. This
implied that they were resistant to all three drugs of
their ARV regimes.
The presence of the K65R also means that tenofovir
(TDF) will not be effective when used in the second-line
regime, and the Q151M mutation commonly confers
multi-drug resistance to NRTIs (AZT, ABC, ddI and
d4T). In seven patients, the presence of one or two
NRTI mutations (M41L, D67N) was also seen, but this
had not yet resulted in drug resistance. Two patients
had virus mutations indicative of the TAM-1 profile
(M41L, L210W, T215S), and two of the TAM-2 profile
(D67N, K70R, T215F, K219Q/R/E). No major mutations
were seen in the protease gene.
The predominant HIV-1 variant in this study popula-
tion was CRF02_AG (n = 26, 56.5%). Other variants
were CRF06_cpx (n = 6, 13%), subtype G (n = 1, 2.1%),
and 13 (28.3%) were unique recombinant forms.
Scaling up highly active antiretroviral therapy
(HAART) to achieve universal access is the current
priority of WHO and the Joint United Nations Pro-
gramme on HIV/AIDS (UNAIDS). Several cohort stu-
dies, using virological monitoring, have shown that ART
treatment in resource-poor settings has efficacy rates
similar to those reported for developed countries [7-12].
However, the few studies reporting on ART using the
public health approach showed more contrasted results,
with virological succes after 12 months ranging from
50% to more than 90% [13,14]. But among these
patients with virological failure, a significant proportion
can be due to adherence problems, as shown in a study
in Cameroon, where only 25% of patients with VLs over
1000 copies/ml were resistant to ARVs after 12 months
[15].
I nc o n t r a s t ,i nt h i ss t u d yi nT o g o ,m o r et h a n8 0 %o f
patients with virological failure at M12 were already
resistant to ARVs, corresponding to 24.5% of all the
patients enrolled in this study. Moreover, since the first-
line regimen included two drugs with low genetic bar-
riers, the majority of patients with HIV harbouring
drug-resistance mutations were resistant to two of the
three drugs from their regimens (25 of 46, or 54.3%);
e i g h to f4 6( 1 7 . 4 % )w e r er e s i s t a n tt oa l ld r u g si nt h e i r
ARV treatments. A total of 11 (23.9%) patients already
harboured mutations conferring resistance to drugs for
second-line regimes, such as TDF (n = 3) or the new
NNRTI, etravirine (n = 8).
This is in agreement with observations from a recent
study in Malawi, which also showed clearly that when
only clinical and CD4 count cell criteria are used to
monitor first-line ART failure, extensive NRTI and
NNRTI resistance emerges, with 23% patients having
resistance profiles that compromise second-line ART
[16]. Importantly, our estimates of drug resistance in
treated patients in Togo are most likely minimal esti-
mates because we used a cross-sectional approach and
only patients who are still under treatment were studied.
Our study does not provide any information on how
many patients dropped out of care or died and how
many of those patients harbour drug-resistance muta-
tions. However, the observed information is useful for
clinicians managing patients and can serve as an indica-
tor of ARV programme efficiency in patients still on
treatment.
In Togo, efforts to provide access to ARV therapy for
infected persons have increased since 2003, and scaling
up of ART started in 2007. However, during the scaling-
up period, the national programme encountered
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July 2010) and corresponding patient characteristics, CD4 counts and viral load values
Patient Age Sex CD4
(cells/
mm
3)
Viral Drug-resistance Mutations Predicition of high level resistance to
following ARVs
ID M0 M12 load NRTI (ex 3TC/FTC) 3TC/
FTC
NNRTI
T3003 28 F 175 50 5.68 M41LM,T215NSTY,
V75MV
M184V Y181C EFV/NVP; 3TC/FTC, D4T, AZT
T3008 32 F 70 36 5.57 K65R, (T69D) - K101E, Y181C, G190S EFV/NVP; TDF
T3013 23 F nt 507 4.75 T69N - K103N, Y181C EFV/NVP
T3017 68 M 53 203 4.88 - M184V (A98AG), K103KN, EFV/NVP; 3TC/FTC
T3029 39 M 21 145 6.34 - M184V K101E, G190A, EFV/NVP; 3TC/FTC
T3031 36 M 100 21 4.20 M41L, T215Y, V75MV, M184V Y181C EFV/NVP; 3TC/FTC, D4T, AZT
T3034 39 M 154 209 4.59 - M184V Y181C EFV/NVP; 3TC/FTC
T3039 33 F 181 264 5.08 - M184V Y181V ETV, EFV/NVP; 3TC/FTC
T3041 47 M 348 218 4.99 - M184V K101E, G190A EFV/NVP; 3TC/FTC
T3042 35 F 16 17 5.23 T69N, Q151M M184V V90I, K103N, Y181C,
G190A
EFV/NVP; 3TC/FTC, ABC, AZT, D4T, DDI,
T3043 37 F 276 255 4.89 - M184V K103N EFV/NVP; 3TC/FTC
T3046 43 M 36 43 4.64 K70R, T215F, K219E M184V Y181C EFV/NVP; 3TC/FTC, AZT, D4T
T3047 32 M 128 254 4.41 - - Y181C, H221HY ETV, EFV/NVP
T3049 33 F 154 338 4.25 - M184V G190A EFV/NVP; 3TC/FTC
T3061 24 F 184 410 3.43 - M184V V106A, NVP; 3TC/FTC
T3067 37 F 143 264 3.32 T69S M184V K103N, EFV/NVP; 3TC/FTC
T3069 40 M 143 163 3.72 T69D, K70R, K219Q M184V Y181C, G190A, H221Y ETV, EFV/NVP; 3TC/FTC
T3071 40 F 80 282 3.43 T69N M184V Y181C EFV/NVP; 3TC/FTC
T3073 45 M 168 58 4.08 - - K103N, Y181C EFV, NVP
E5009 35 M 78 43 5.56 D67N, K65R - V106M, Y188C EFV/NVP; TDF
E5011 50 M 102 148 3.32 - M184V Y181C EFV/NVP; 3TC/FTC
E5013 32 F 57 112 3.20 T69N M184V Y181C EFV/NVP; 3TC/FTC, DDI
E5016 33 F 173 399 4.20 - - Y181CY EFV/NVP
E5017 47 M nt 182 4.23 - M184V Y181V ETV; 3TC/FTC
E5020 22 F 147 365 3.04 - M184V K103N EFV/NVP; 3TC/FTC
E5024 42 M 78 197 4.41 - M184V (V90I), V106A, EFV/NVP; 3TC/FTC
E5025 48 F 51 71 3.32 K65R - Y181C, K103N EFV/NVP; TDF
E5027 29 F 35 84 5.08 - - K103KN EFV/NVP
E5032 39 M 70 13 5.45 - - G190AG, K103N EFV/NVP
E5043 46 M 27 93 3.11 - M184V Y181V, (A98S) ETV; 3TC/FTC
E5044 60 F nt 517 4.78 - M184V Y188L EFV/NVP; 3TC/FTC
E5047 52 F 57 57 4.54 - - Y181C, K103N EFV/NVP
E5053 35 M 99 66 5.74 (D67N, L210W) - Y181C, G190AG, (V90I) EFV/NVP
E5059 41 M 118 40 4.59 (T69N ) - Y181C EFV/NVP
E5061 31 F 34 72 4.72 M41L M184I, Y181C, V90IV, A98AG,
H221Y
ETV, EFV/NVP; 3TC/FTC
E5068 30 F 152 339 3.15 - M184V K103N, (A98G) EFV/NVP; 3TC/FTC
C7003 34 M 98 288 4.30 - M184V V106A, NVP; 3TC/FTC
C7004 38 F 185 540 4.45 - M184V K103N, Y181C, (V90IV) EFV,NVP; 3TC/FTC
C7012 40 M 75 267 3.23 - M184V Y181C EFV/NVP; 3TC/FTC
C7017 42 M 12 40 4.98 - - K103N EFV/NVP
C7022 31 F 64 310 4.08 - M184V Y181C EFV/NVP; 3TC/FTC
C7023 27 F 101 83 3.36 - M184MV K103N, (A98AG) EFV/NVP; 3TC/FTC
C7024 20 F 35 84 4.00 T69D, D67G, K70R,
K219Q
M184V Y181C, G190A, H221Y ETV, EFV/NVP; 3TC/FTC, AZT, DDI
C7028 33 M 72 12 4.36 - - Y181C, K103N EFV/NVP
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substitution with the same molecules, administered
separately as individual pills instead of as fixed-dosed
combinations, or even interruption of the treatment.
Overall, our study shows major problems with the
ART programme in Togo during the first year of scaling
up HAART in the country, but does not reflect the
situation in Togo three years later, which could be dif-
ferent. In a previous study, we reported also that 10% of
recently diagnosed ARV-naive HIV-1 positive patients in
2007 were infected with HIV strains that already har-
boured a drug-resistance mutation [6]. However, the
possibility cannot be excluded that some of the patients
included in this and our previous study [6] were not
ART naïve and already harboured ARV-resistant strains
because this was based on self-reported information by
the patients.
Conclusions
Our results show clearly that the emergence of HIV
drug resistance is of increasing concern in countries
where ART is now widely used, and can compromise
long-term success in treatment outcomes. Since indivi-
dual patient monitoring for viral load and drug resis-
tance is not yet possible, the system that WHO
(HIVRESNET) has established for the surveillance of
transmitted drug resistance and the monitoring of ART
resistance at sentinel sites should be implemented in
order to inform health authorities on the efficiency of
first- and second-line ART and allow recommendations
on future ART strategies [17]. The high number of
resistant strains observed in Togo among ARV-naïve
patients and patients on ART at the onset of ART scal-
ing up in the country needs further attention, and addi-
tional studies are needed to evaluate actual drug-
resistance rates.
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